Article, Media, News
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Article, News
Phase 1b study of Prescient Therapeutics’ (ASX: PTX) PTX-100 shows excellent safety and promising efficacy in TCL patients
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased at the annual meeting of the American Society of Hematology (ASH) in…
Article, News
Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt of AU$2.4 million as R&D Tax Incentive rebate for the…
Article, News
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Article, News
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Article, News
Why are clinical advances by this small-cap ASX biotech in FY23 so significant?
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal of developing targeted cancer treatments. In the latest financial year…
Article, News
Prescient Therapeutics (ASX:PTX) announces US-based Dr Ellen Feigal as new inclusion to Board
ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr Ellen Feigal to PTX’s Board. Notably, Dr Feigal is an…
Article, News
Prescient Therapeutics (ASX:PTX) makes progress in March 2023 quarter
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its Activities Report for the quarter ended March 2023. Aside from…
Article, News
Prescient (ASX:PTX) reports promising clinical data for PTX-100 in relapsed and refractory TCL – Kalkine Media
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of its PTX-100 compound in patients with relapsed and refractory T…
Article, News
Prescient Therapeutics (ASX:PTX) lands FDA Orphan Drug status for PTX-100, shares soar – Kalkine Media
Australia’s clinical-stage oncology company Prescient Therapeutics (ASX: PTX) — developing targeted therapies (PTX-100 and PTX-200) and cellular therapies (OmniCAR, CellPryme-M, and CellPryme-A) — has received…